{
  "url": "https://openlegislation.uk/eu-regulation-2008-1272/annex-I/division-3/division-3.9/division-3.9.2/division-3.9.2.7/division-3.9.2.7.3",
  "json_url": "https://openlegislation.uk/eu-regulation-2008-1272/annex-I/division-3/division-3.9/division-3.9.2/division-3.9.2.7/division-3.9.2.7.3.json",
  "legislation": "eur/2008/1272",
  "legislation_title": "Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2008-1272",
  "path": "annex/I/division/3/division/3.9/division/3.9.2/division/3.9.2.7/division/3.9.2.7.3",
  "kind": "division",
  "number": "3.9.2.7.3",
  "heading": "Evidence from appropriate studies in experimental animals can furnish much more detail, in the form of clinical observations, haematology, clinical chemistry, and macroscopic and microscopic pathological examination, and this can often reveal hazards that may not be life-threatening but could indicate functional impairment. Consequently all available evidence, and relevance to human health, shall be taken into consideration in the classification process, including but not limited to the following toxic effects in humans and/or animals:",
  "text": "(a) morbidity or death resulting from repeated or long-term exposure. Morbidity or death may result from repeated exposure, even to relatively low doses/concentrations, due to bioaccumulation of the substance or its metabolites, and/or due to the overwhelming of the de-toxification process by repeated exposure to the substance or its metabolites;\n(b) significant functional changes in the central or peripheral nervous systems or other organ systems, including signs of central nervous system depression and effects on special senses (e.g. sight, hearing and sense of smell);\n(c) any consistent and significant adverse change in clinical biochemistry, haematology, or urinalysis parameters;\n(d) significant organ damage noted at necropsy and/or subsequently seen or confirmed at microscopic examination;\n(e) multi-focal or diffuse necrosis, fibrosis or granuloma formation in vital organs with regenerative capacity;\n(f) morphological changes that are potentially reversible but provide clear evidence of marked organ dysfunction (e.g., severe fatty change in the liver);\n(g) evidence of appreciable cell death (including cell degeneration and reduced cell number) in vital organs incapable of regeneration.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2008/1272/annex/I/division/3/division/3.9/division/3.9.2/division/3.9.2.7/division/3.9.2.7.3",
    "retrieved_at": "2026-11-01T14:51:47.470832+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}